BRPI0408295A - uso de um composto - Google Patents

uso de um composto

Info

Publication number
BRPI0408295A
BRPI0408295A BRPI0408295-8A BRPI0408295A BRPI0408295A BR PI0408295 A BRPI0408295 A BR PI0408295A BR PI0408295 A BRPI0408295 A BR PI0408295A BR PI0408295 A BRPI0408295 A BR PI0408295A
Authority
BR
Brazil
Prior art keywords
compound
alzheimer
medicament
age
disease
Prior art date
Application number
BRPI0408295-8A
Other languages
English (en)
Inventor
Mark Steven Shearman
Mervyn Turner
Original Assignee
Merck Sharp & Dohme
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme, Merck & Co Inc filed Critical Merck Sharp & Dohme
Publication of BRPI0408295A publication Critical patent/BRPI0408295A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4747—Quinolines; Isoquinolines spiro-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

"USO DE UM COMPOSTO". é apresentado o uso de um composto de fórmula (I), ou um seu sal farmaceuticamente aceitável, para a fabricação de um medicamento para o tratamento do declínio cognitivo relacionado à idade ou impedimento cognitivo brando, em particular com vistas a prevenir ou retardar o começo do mal de Alzheimer.
BRPI0408295-8A 2003-03-14 2004-03-08 uso de um composto BRPI0408295A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45458903P 2003-03-14 2003-03-14
PCT/GB2004/000983 WO2004080459A1 (en) 2003-03-14 2004-03-08 Method for treating mild cognitive impairment and for preventing or delaying alzheimer’s disease

Publications (1)

Publication Number Publication Date
BRPI0408295A true BRPI0408295A (pt) 2006-03-07

Family

ID=32990914

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0408295-8A BRPI0408295A (pt) 2003-03-14 2004-03-08 uso de um composto

Country Status (13)

Country Link
US (1) US20060241133A1 (pt)
EP (1) EP1605940A1 (pt)
JP (1) JP2006520371A (pt)
KR (1) KR20050109990A (pt)
CN (1) CN1794992A (pt)
AU (1) AU2004218871A1 (pt)
BR (1) BRPI0408295A (pt)
CA (1) CA2518886A1 (pt)
IS (1) IS8004A (pt)
MX (1) MXPA05009850A (pt)
NO (1) NO20054714L (pt)
RU (1) RU2005131845A (pt)
WO (1) WO2004080459A1 (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0313772D0 (en) * 2003-06-13 2003-07-23 Merck Sharp & Dohme Therapeutic treatment
US7745484B2 (en) 2005-11-21 2010-06-29 Amgen Inc. Beta-secretase modulators and methods of use
US7838676B2 (en) 2005-11-21 2010-11-23 Amgen Inc. Beta-secretase modulators and methods of use
JP5274258B2 (ja) 2005-11-21 2013-08-28 アムジエン・インコーポレーテツド β−セクレターゼ調節物質及び使用方法
US7872009B2 (en) 2005-11-21 2011-01-18 Amgen Inc. Beta-Secretase modulators and methods of use
WO2008147547A1 (en) 2007-05-25 2008-12-04 Amgen Inc. Substituted hydroxyethyl amine compounds as beta-secretase modulators and methods of use
EP2167471B1 (en) 2007-05-25 2013-10-16 Amgen Inc. Substituted hydroxyethyl amine compounds as beta-secretase modulators and methods of use
US7803809B2 (en) 2008-11-12 2010-09-28 Amgen Inc. Substituted pyrano [2,3-b] pyridinamine compounds as beta-secretase modulators and methods of use
US8426447B2 (en) * 2008-09-11 2013-04-23 Amgen Inc. Spiro-tricyclic ring compounds as beta-secretase modulators and methods of use
EP2504330A1 (en) 2009-11-23 2012-10-03 Amgen Inc. Amino heteroaryl compounds as beta-secretase modulators and methods of use
EP2504315A1 (en) 2009-11-23 2012-10-03 Amgen Inc. Amino heteroaryl compounds as beta-secretase modulators and methods of use
CA2788363A1 (en) 2010-01-19 2011-07-28 Amgen Inc. Amino heteroaryl compounds as beta-secretase modulators and methods of use
US8883782B2 (en) 2010-03-15 2014-11-11 Amgen Inc. Spiro-tetracyclic ring compounds as beta-secretase modulators and methods of use
JP5584352B2 (ja) 2010-03-15 2014-09-03 アムジエン・インコーポレーテツド β−セクレターゼ調節剤としてのアミノ−ジヒドロオキサジン系およびアミノ−ジヒドロチアジン系スピロ化合物ならびにそれらの医学的用途
US9346827B2 (en) 2011-02-07 2016-05-24 Amgen Inc. 5-amino-oxazepine and 5-amino-thiazepane compounds as beta secretase antagonists and methods of use
JP2014526560A (ja) 2011-09-21 2014-10-06 アムジエン・インコーポレーテツド β‐セクレターゼ調節因子としてのアミノオキサジン化合物およびアミノジヒドロチアジン化合物および使用方法
WO2014078314A1 (en) 2012-11-15 2014-05-22 Amgen Inc. Amino-oxazine and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use
LU92126B1 (fr) * 2012-12-31 2014-07-01 Cesa Alliance Sa Composé pharmaceutique pour la prévention et le traitement d'un trouble ou d'une maladie de la mémoire, neurodégénérative ou neuronale

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4902680A (en) * 1984-10-29 1990-02-20 Chaovanee Aroonsakul Treating central nervous system diseases
NZ258412A (en) * 1992-12-11 1997-01-29 Merck & Co Inc Spiro-fused piperidine derivatives and pharmaceutical compositions
EP0823904A4 (en) * 1995-04-19 1998-09-09 Merck & Co Inc Process for the preparation of spiroindolines
US5767124A (en) * 1995-10-27 1998-06-16 Merck & Co., Inc. Polymorphic forms of a growth hormone secretagogue
US6028196A (en) * 1995-10-27 2000-02-22 Merck & Co., Inc. Process for the preparation of a growth hormone secretagogue
JP2000511885A (ja) * 1996-05-07 2000-09-12 メルク エンド カンパニー インコーポレーテッド 成長ホルモン分泌促進薬による睡眠の強化
US6046333A (en) * 1996-10-25 2000-04-04 Merck & Co., Inc. Convergent process for the preparation of a growth hormone secretagogue
AU757907B2 (en) * 1998-09-03 2003-03-13 Neuren Pharmaceuticals Limited Neuroprotection
ATE304373T1 (de) * 1999-12-28 2005-09-15 Kaken Pharma Co Ltd Nervenschutzmittel
EP1149583A3 (en) * 2000-04-13 2001-11-14 Pfizer Products Inc. Combinations of corticotropin releasing factor antagonists and growth hormone secretagogues

Also Published As

Publication number Publication date
RU2005131845A (ru) 2006-02-10
MXPA05009850A (es) 2005-12-06
KR20050109990A (ko) 2005-11-22
CA2518886A1 (en) 2004-09-23
EP1605940A1 (en) 2005-12-21
US20060241133A1 (en) 2006-10-26
IS8004A (is) 2005-08-29
CN1794992A (zh) 2006-06-28
JP2006520371A (ja) 2006-09-07
WO2004080459A1 (en) 2004-09-23
NO20054714L (no) 2005-11-16
NO20054714D0 (no) 2005-10-13
AU2004218871A1 (en) 2004-09-23

Similar Documents

Publication Publication Date Title
BRPI0408295A (pt) uso de um composto
BR0316948A (pt) Composto, formulação farmacêutica, e, uso de um composto
NL300889I2 (nl) Trifluridine in combinatie met tipiracilhydrochloride
BR0315337A (pt) Composto, formulação farmacêutica, e, método para tratar câncer
BR0308429A (pt) Aroilpiridinonas monocìclicas como agentes antiinflamatórios
BRPI0416628A (pt) uso de compostos orgánicos
BR0213358A (pt) Uso de flibanserina
BRPI0519124A2 (pt) composto, mÉtodo para tratar, prevenir ou melhorar obesidade e doenÇas relacionadas e/ou sintomas das mesmas, composiÇço farmacÊutica, uso de composto, e, combinaÇço
BRPI0417771A (pt) heterociclos azabicìclicos como moduladores de receptor canabinóides
BRPI0108977B8 (pt) compostos azacíclicos, composição farmacêutica e uso de um composto ou sal farmaceuticamente aceitável do mesmo
BRPI0412893A (pt) composto, composição farmacêutica, uso de um composto, e, métodos de prevenção, tratamento ou melhora de doenças ou condições inflamatórias, ou doenças ou condições oftálmicas, de tratamento ou melhora de cáncer e para a produção de um composto
BRPI0408784A (pt) método para usar um composto
MA27372A1 (fr) Forme posologique de pramipexole à administration une fois par jour
BR0109703A (pt) Derivados de piperazina
DOP2002000429A (es) Imidazotriazinas
BRPI0407097A (pt) Antagonista do casr
BR0210122A (pt) Composto ou um sal farmaceuticamente aceitável do mesmo, método para o tratamento ou prevenção de uma doença, uso do composto ou de seu sal, e, método para preparar o mesmo
BRPI0406883A (pt) Composto, composição farmacêutica, método de tratar um distúrbio, e, uso de um composto
BRPI0407234A (pt) Heterociclos substituìdos
BR0013065A (pt) Método e composto para tratar de uma doença associada com recrutamento e/ ou ativação aberrante de leucócitos
BR0316458A (pt) Composto, composição farmacêutica, método de tratamento ou prevenção de doenças, método para intensificar a cognição em um paciente saudável, e, uso de um composto
BR0311189A (pt) Composições farmacêuticas contendo polimorfo a de flibanserin
BR0113590A (pt) 7-oxo-piridopirimidinas
BRPI0416882A (pt) composto, composição farmacêutica, método de tratar um distúrbio, e, uso de um composto
PL360492A1 (en) Use of pamoic acid or one of its derivatives, or one of its analogues, for the preparation of a medicament for the treatment of diseases characterised by deposits of amyloid aggregates

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]